Liminatus Pharma, Inc.
corporate_fare Company Profile
Liminatus Pharma, Inc. (NASDAQ:LIMN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for LIMN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 18 rated 8 or above. Recent SEC coverage for LIMN spans 8-K, 10-Q, 4, SCHEDULE 13D/A.
Recent high-impact activity:
- Liminatus Pharma Executes 1-for-50 Reverse Split to Regain Nasdaq Compliance
- Liminatus Pharma Executes 1-for-50 Reverse Stock Split to Regain Nasdaq Compliance
- Liminatus Pharma 10-Q: Going Concern Doubt, Material Weaknesses, Nasdaq Deadline Sept 3
- Merger lifts Liminatus Pharma equity above $2.5M, but Nasdaq compliance decision still pending
- Nasdaq Denies Second Extension; Delisting Decision Looms for Liminatus Pharma
Financial Snapshot
Short Interest & Short Volume
1.65 days to coverFINRA reported short interest of 47,913 shares in LIMN as of the October 30, 2026 settlement, a 20.9% increase from the prior period — about 1.6 days to cover at its recent average daily volume. On November 20, 2026, 35.0% of LIMN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for LIMN, detected from its recent SEC filings · based on capital-structure filings through 2026-06-24.
Warrant Exercise Price Reduced · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →